Welcome to our dedicated page for Enovix Corporation SEC filings (Ticker: ENVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enovix Corporation (ENVX) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory documents, along with AI-powered summaries to help interpret complex disclosures. As a Nasdaq-listed battery technology company focused on advanced lithium-ion cells and 100% active silicon-anode architectures, Enovix uses its SEC reports to describe financial performance, capital structure, risk factors and material events.
Through this page, you can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss Enovix’s business model, battery technology, manufacturing footprint in regions such as Malaysia and South Korea, and markets including smartphones, smart eyewear, IoT, industrial and defense applications. Our AI tools highlight key sections, such as revenue trends, operating expenses, liquidity, and the Risk Factors and MD&A discussions referenced in the company’s press releases.
You can also follow current reports on Form 8-K, where Enovix has disclosed items such as quarterly financial results, a warrant dividend distribution, authorization of a share repurchase plan, and the issuance of 4.75% Convertible Senior Notes due 2030 with related capped call transactions. These filings explain terms of the notes, conversion conditions, redemption provisions and the intended use of proceeds, including potential acquisitions in the battery ecosystem.
In addition, this page surfaces registration statements, prospectus supplements and related exhibits that describe the warrant program (ENVXW), share issuance mechanics and legal opinions, as well as any future Form 4 insider transaction reports when available. AI-generated overviews help clarify technical language, summarize covenant and event-of-default provisions, and point out changes in capital structure or share count. Together, these tools allow investors to navigate Enovix’s regulatory history more efficiently while still relying on the underlying SEC documents as the authoritative source.
Enovix Corporation filed its Annual Report on Form 10-K for the fiscal year ended December 28, 2025. The company describes its proprietary 3D silicon-anode cell architecture and the AI-1™ battery platform, reports manufacturing expansion in Malaysia and South Korea, and states Fab2 passed ISO 9001 and customer audits. The report discloses a volumetric energy density test of 935Wh/L for the AI-1 smartphone cell and highlights ongoing scale-up, supply-chain, and qualification risks.
Enovix Corporation is asking shareholders to vote at its virtual 2026 annual meeting on June 11, 2026, including electing eight directors, approving executive pay on an advisory basis, and ratifying Deloitte & Touche LLP as auditor.
In 2025 Enovix generated record revenue of $31.8 million, up 38% year over year, with non-GAAP gross margin improving to 23%. The company ended the year with about $621 million in cash and marketable securities and a global sales pipeline of roughly $100 million, largely in defense and drone applications.
Enovix executed approximately $60 million of share repurchases under a program expanded to $75 million, issued $360 million of convertible senior notes and a warrant dividend that produced $224 million of net proceeds, and continued scaling manufacturing in Malaysia and South Korea. The proxy highlights a pay-for-performance program in which about 92% of the CEO’s 2025 target compensation was at risk, with annual and long-term incentive payouts reduced where operational and financial goals were not fully achieved.
Enovix Corp President and CEO Rajendra K. Talluri reported a routine tax-related share disposition. On the transaction date, 17,651 shares of common stock were withheld at $6.62 per share to cover tax obligations tied to the vesting of restricted stock units.
After this withholding, he directly holds 3,080,145 shares of Enovix common stock. This total includes 2,039,397 shares issuable upon future RSU vesting and settlement, 47,775 vested performance RSUs scheduled for release in March 2027, and 259,611 additional performance RSUs scheduled for release in April 2027 and April 2028.
Enovix Corp Chief Financial Officer Ryan A. Benton reported an automatic share disposition tied to taxes, not an open-market sale. On the vesting of restricted stock units (RSUs), 79,725 shares of common stock were withheld at $6.36 per share to satisfy tax withholding obligations.
Following this tax-withholding disposition, Benton directly holds 922,968 shares of Enovix common stock. His position also includes 848,005 additional shares issuable upon future vesting and settlement of RSUs granted to him.
Enovix Corp Chief Accounting Officer Kristina Truong reported routine share withholdings to cover taxes tied to stock awards. On April 8, 10, and 13, 2026, a total of 2,945 shares of Enovix common stock were withheld at prices between $5.73 and $6.09 per share to satisfy tax withholding obligations on vesting restricted stock units.
These transactions, coded "F" as tax-withholding dispositions, were not open-market sales and did not generate trading proceeds for Truong. After the latest withholding, she directly holds 312,154 shares of Enovix common stock, including substantial shares underlying unvested RSUs and performance RSUs described in the footnotes.
Enovix Corp Chief Legal Officer Arthi Chakravarthy reported a routine tax-related share disposition. On April 8, 4,295 shares of common stock were withheld at $5.73 per share to cover tax obligations from restricted stock unit vesting. After this, Chakravarthy directly holds 606,712 shares, including 401,351 shares tied to RSUs and performance RSUs scheduled for release between March 2027 and April 2028.
Enovix Corp President and CEO Rajendra K. Talluri had shares withheld to cover taxes tied to equity compensation. On April 8, 2026, 17,960 shares of common stock were disposed of at $5.73 per share to satisfy tax withholding obligations upon vesting of restricted stock units, not through an open-market sale. Following this tax-withholding disposition, he directly holds 3,097,796 shares, including 2,072,731 shares issuable from RSUs and additional performance RSUs scheduled for release between March 2027 and April 2028.
Truong Kristina reported acquisition or exercise transactions in this Form 4 filing.
Enovix Corp Chief Accounting Officer Kristina Truong received a grant of 99,601 shares of common stock in the form of restricted stock units at no cash cost. These RSUs will vest in 12 equal quarterly installments starting on April 1, 2026, conditioned on her continued service.
Following this award, she holds 315,099 shares and rights, including 229,040 RSUs and vested performance RSUs scheduled for release in March 2027, April 2027, and April 2028. This filing reflects compensation rather than open‑market trading.
Chakravarthy Arthi reported acquisition or exercise transactions in this Form 4 filing.
Enovix Corp Chief Legal Officer Arthi Chakravarthy received an equity award of 159,362 shares of common stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost and will vest in 12 equal quarterly installments starting from April 1, 2026, conditioned on continued service.
After this grant, Chakravarthy is reported as holding 611,007 shares of Enovix common stock, including 409,461 shares issuable upon vesting and settlement of RSUs, 10,393 vested performance RSUs scheduled for release in March 2027, and 58,500 additional performance RSUs scheduled for releases in April 2027 and April 2028.
Benton Ryan A reported acquisition or exercise transactions in this Form 4 filing.
Enovix Corp Chief Financial Officer Ryan A. Benton received a stock-based compensation award of 249,003 shares of common stock on April 1, 2026, in the form of restricted stock units (RSUs). The award was granted at no cash cost per share and is structured to vest in 12 equal quarterly installments starting from April 1, 2026, as long as he remains in continuous service through each vesting date.
Following this grant, Benton holds 1,002,693 shares of Enovix common stock, which includes 997,755 shares issuable upon future vesting and settlement of previously granted RSUs. This filing reflects a compensation-related equity grant rather than an open-market purchase or sale.